About Pentara


Suzanne Hendrix, Ph.D.
President and CEO

Suzanne Hendrix, Ph.D.
President and CEO


Suzanne Hendrix received her Ph.D. in Mathematics from Boston University and has spent the last 29 years as a statistician focusing on clinical trials research in many different indications. She has extensive experience designing clinical trials, writing statistical analysis plans, running analyses, writing statistical reports, interacting with the FDA, and preparing manuscripts for publication. In addition to her experience assisting the development of software for understanding large, complex datasets through graphical means, Dr. Hendrix is experienced at communicating statistical concepts in an understandable way. Dr. Hendrix has assisted in revolutionary software development for understanding large, complex datasets through graphical means and communicates statistical concepts in an understandable way. For the past 17 years, Dr. Hendrix has focused her research and analytical skills on statistical issues in Alzheimer's disease, including identifying appropriate outcomes, addressing measurement issues, demonstrating disease modification, and optimizing the design of clinical trials. She has interacted with the division of Neurology products at the FDA and with the EMEA by acting as a scientific advisor for these issues. Currently Dr. Hendrix is an independent consultant in the pharmaceutical industry, primarily supporting clinical trial design and optimization in neurological indications, with particular focus on Alzheimer's disease. Dr. Hendrix has researched methods for discerning disease modification of a treatment, and has proposed novel approaches to this problem.


Sam Dickson, Ph.D.
Senior Director, Statistics and Data Management

Sam Dickson, Ph.D.
Senior Director, Statistics and Data Management


Sam Dickson received his Ph.D. in Statistics and Bioinformatics from North Carolina State University. He started working with clinical trial data in 2003 and has worked on trials with the US government, universities, large and small pharmaceutical companies, and biotech companies on drugs, biologics, and medical devices across several therapeutic areas. In addition to clinical and pre-clinical studies, he has also worked as a statistical geneticist working with genome-wide association studies and next generation sequencing. When designing or analyzing studies, he understands that sound methodologies and persuasive presentation are both important because getting the right answer and helping people understand that it’s right are not the same thing. Dr. Dickson believes everyone is a Bayesian at heart even though he has spent most of his career designing and analyzing studies using frequentist methods. He has worked with Pentara on a number of projects since 2014 and became full time in 2018.


Noel Ellison
Director, Biostatistics

Noel Ellison
Director, Biostatistics


Noel Ellison received her Masters in Statistics from Brigham Young University in 2012, and has worked in the pharmaceutical industry for 7 years. Ms. Ellison has experience designing clinical trials, writing statistical analysis plans, running analyses, writing statistical reports and preparing manuscripts for publication.She works with Suzanne Hendrix focusing on statistical issues in Alzheimer's disease such as identifying appropriate outcomes, addressing measurement issues, demonstrating disease modification and optimizing clinical trial design and analysis.


Kent Hendrix
Director, Data Management and Statistical Programming

Kent Hendrix
Director, Data Management and Statistical Programming


Kent Hendrix has 29 years experience in the Pharmaceutical industry, all aspects of statistical programming in SAS, and has handled a broad variety of clinical trials and data analysis projects. He has worked on 6 NDAs and managed multiple groups of SAS programmers. Mr. Hendrix has taught SAS programming at Brigham Young University and AP Statistics and Computer Science at the high school level. He developed a SAS program Log File Analysis tool that helps SAS programmers debug their code faster. He developed a web based clinical trial management software that handles the enrollment and randomization of subjects, drug distribution to sites, and allocation to subjects. It has managed global phase 1, 2, and 3 clinical trials. He holds a 10th degree black belt in Bushikai Kishindo Martial Arts.

Galasko DR, Graff-Radford N, May S, Hendrix S, Cottrell BA, Sagi SA, Mather G, Laughlin M, Zavitz KH, Swabb E, Golde TE, Murphy MP, Koo EH (2007) Safety, Tolerability, Pharmacokinetics, and Abeta Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals. Alzheimer Dis Assoc Disord. 21 (4):292-299.


Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G; European Task Force Group (incl. Hendrix S). Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2008 May;7(5):436-50.


Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA; Tarenflurbil Phase II Study investigators (2008) Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008 Jun;7(6):483-93. Epub 2008 Apr 29.


Hendrix SB, Wilcock GK; What We Have Learned from the Myriad Trials. Journal of Nutrition, Health and Aging. 2009 Apr: 13(4):362-364.


Vellas B, Aisen P, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni B, Weiner M, Schneider L, Gauthier S, Gispen-Wied C, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H; Prevention Trials in Alzheimer’s Disease: AN EU-US task Force report. From the Toulouse Task Force 2010


Shankle R, Atri A, Hendrix S: Improving measurement methodology to detect treatment effect in clinical trials [abstract]. The Journal of Nutrition, Health & Aging© Volume 15, Supplement 1, 2011, s3.


Hendrix SB: Requiring an amyloid-β1–42 biomarker may improve the efficiency of a study, and simulations may help in planning studies. Alzheimer’s Research & Therapy 2011, 3:X.


Hendrix SB: Measuring clinical progression in MCI and pre-MCI populations: Time as the Gold Standard. Commisioned review article currently under review, Alzheimer’s Research & Therapy 2012

Get a Quote »

Email

info@pentaracorp.com

Telephone

1-801-487-5622

Monday - Friday
9:00AM - 5:00 PM Mountain Time


Visit Us

2261 East 3300 South
Suite 200
Millcreek, UT 84109


Career Opportunities

Pentara is always interested in connecting with SAS programmers and statisticians who are or could see themselves in the Salt Lake City area.

Please contact us at

opportunities@pentaracorp.com